Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Navarixin in Moderate to Severe COPD
NCT01006616Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- Oct 2009
- Primary completion
- Mar 2011
01
Overview
A Phase 2 trial of navarixin in chronic obstructive pulmonary disease (COPD), sponsored by Merck & Co.. Started Oct 2009; status: terminated.
02
Drugs
navarixin
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT01006616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01006616.